Nexalin Technology Inc

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices helps people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury (mTBI). The company said that the study, conducted at the University of California San Diego, achieved a statistically significant decrease in post-concussion symptoms and post-traumatic stress disorder symptoms for patients treated with Nexalin's non-invasive, frequency-based deep brain stimulation device when compared to the control group.

Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veterans

Previously served as Acting General Counsel to the Department of Veterans Affairs Previously served as Acting General Counsel to the Department of Veterans Affairs

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology

Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA)

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo Data published in Journal of Psychiatric Research suggests that the Gen-2 tACS device may have the potential to reduce chronic insomnia and consistently improve sleep quality and efficiency in adults Chronic insomnia is often associated with fatigue, mood changes, difficulty concentrating and impaired daytime functioning HOUSTON, TEXAS, March 06, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced positive results of a clinical study of its Gen-2 tACS device (“tACS”) for the treatment of chronic insomnia. This clinical study, conducted at Xuanwu Hospital of Capital Medical University in Beijing and Beijing Anding Hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Company's International Reach Expanding with Latest Regulatory Approval Company's International Reach Expanding with Latest Regulatory Approval

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company's non-invasive, frequency-based deep brain stimulation device.  The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System,” covers the core technology utilized in the Company's Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner.

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by a physician Photo: HALO™ Clarity headset HOUSTON, TEXAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today unveiled its Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device designed to treat a variety of mental health conditions, including Major Depressive Disorder (MDD), addiction and substance use disorder, Alzheimer's disease, traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), chronic pain and other potentially-applicable stress-related neuropsychiatric disorders. The HALO™ Clarity utilizes an advanced technique, Deep Intracranial Frequency Stimulation (DIFS™), to penetrate structures deep in the mid-brain that are associated with mental health disorders.

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Results published in General Psychiatry, a leading peer-reviewed journal Results published in General Psychiatry, a leading peer-reviewed journal

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( “Advisory Board”) to support its non-invasive, frequency-based, deep-brain stimulation devices within U.S. government agencies. Spearheaded by David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy and leading government affairs veteran, the Advisory Board will work closely with the Company in formulating the strategic direction and implementing the commercialization of the Company's devices.  The Advisory Board is the latest Company initiative following its establishment of Nexalin America, a division aimed at fostering and enhancing relationships within and throughout federal government and public sector organizations including the U.S. Department of Defense (“DoD”), U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services..

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health disease Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health disease

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures

HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, including the results of a study in patients with migraine headaches, which indicated a substantial and statistically significant benefit in patients.  The clinical trial was funded by the Company's joint venture partner, Wider Come Limited (“Wider”), and its related companies, and was conducted at the Vertigo Center, Department of Neurology, Second Affiliated Hospital of Zhengzhou University.

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participating in a live interview with the “Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show today, Thursday, August 3rd, 2023 at 3:00 PM ET.

Nexalin's CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time

HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,” aimed at fostering relationships within the U.S. Department of Defense, U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services. Nexalin America will focus on engaging and collaborating with these U.S. government agencies in order to enable their personnel to have access to, and benefit from, Nexalin's non-invasive, frequency-based, deep-brain stimulation devices.  Nexalin anticipates the U.S. government's use of its groundbreaking technology to treat PTSD, traumatic brain injury, anxiety, depression, insomnia and other targeted indications.

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, depression and other indications Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, depression and other indications

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's tACS Devices in the Asia Pacific Region

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022.

Nexalin Technology Provides 2022 Year-End Business Update

HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory.

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

CytomX Therapeutics

Ensysce Biosciences

NeuroOne Medical Technologies Corp

Taysha Gene Therapies

Biotech penny stocks to watch this week. Are they a buy now?

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

The Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanying warrants to purchase 2,315,000 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock with an exercise price of $4.15 per share at a combined offering price of $4.15, for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, Nexalin has granted the underwriters a 45-day option to purchase up to an additional 347,250 shares of common stock and/or warrants to purchase 347,250 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount, of which Maxim Group LLC has exercised its option to purchase an additional 347,250 warrants.

Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of  2,315,000 shares of its Common Stock and  2,315,000 accompanying warrants to purchase up to  2,315,000 shares of common stock. Each share of common stock is being sold together with one Warrant, each to purchase one share of common stock with an exercise price of $4.15 per share at a combined offering price of $4.15, for gross proceeds of approximately $9,607,250 million, before deducting underwriting discounts and offering expenses. In addition, Nexalin has granted the underwriters a 45-day option to purchase up to an additional 347,250 shares of common stock and/or Warrants to purchase up to 345,250 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount. All of the shares of common stock and warrants are being offered by the Company.

News for Nexalin Technology Inc Stock (NXL)